RecruitingNCT06787105

Fruquintinib in Patients With Metastatic Colorectal Cancer

Fruquintinib in Patients With Metastatic Colorectal Cancer: A Prospective, Multicenter, Observational Study

Sponsor

iOMEDICO AG

Enrollment

150 participants

Start Date

Feb 17, 2025

Study Type

OBSERVATIONAL

Conditions

Metastatic Colorectal Cancer (Mcrc)

Summary

FRUQUENT is an observational study in Germany. The goal of the study is to evaluate how well Fruquintinib works to treat patients with metastatic colorectal cancer that have previously been treated with available standard therapies. To this end, it will be analyzed how well patients respond to the therapy in the clinical routine. Further points of interest to the study are survival data, safety data, the use of medical care facilities, and the quality of life of patients treated with Fruquintinib. Participants will be treated as decided by the treating physician and according to their routine practice. FRUQUENT is accompanied by a translational research project combining real-world clinical data with foundational research to stratify patient collectives in regards to the therapeutic benefit of fruquintinib.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This real-world study is tracking how well fruquintinib works and how safe it is in patients in Germany with metastatic colorectal cancer (bowel cancer that has spread) who have already tried multiple standard treatments. It follows patients receiving this drug as part of their regular clinical care. **You may be eligible if...** - You are 18 or older - You have metastatic colorectal cancer - You have already been treated with standard chemotherapy regimens (fluoropyrimidine, oxaliplatin, irinotecan), anti-VEGF therapy, and anti-EGFR therapy (if applicable) - Your cancer progressed on or you could not tolerate trifluridine/tipiracil or regorafenib - Your doctor has prescribed fruquintinib as per the approved German guidelines - You have signed informed consent **You may NOT be eligible if...** - You have not received the required prior treatments - Fruquintinib is not indicated for your specific situation per the drug label Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(42)

Hämatologikum Biberach

Biberach, Baden-Wurttemberg, Germany

Praxis für interdisziplinäre Onkologie & Hämatologie

Freiburg im Breisgau, Baden-Wurttemberg, Germany

Onkologische Schwerpunktpraxis

Heidelberg, Baden-Wurttemberg, Germany

MVZ für Hämatologie und Onkologie Ravensburg GmbH - Studienzentrum

Ravensburg, Baden-Wurttemberg, Germany

Zentrum Ambulante Onkologie

Schorndorf, Baden-Wurttemberg, Germany

ze:ro Praxen MVZ für Innere Medizin Weinheim

Weinheim, Baden-Wurttemberg, Germany

MVZ am Klinikum Aschaffenburg GmbH

Aschaffenburg, Bavaria, Germany

Schwerpunktpraxis Hämatologie & Internistische Onkologie

Fürth, Bavaria, Germany

Onkologie Hof MVZ GmbH

Hof, Bavaria, Germany

Dr. Vehling-Kaiser MVZ GmbH Landshut

Landshut, Bavaria, Germany

Hämatologie und Onkologie München-Pasing MVZ GmbH

München, Bavaria, Germany

Praxis Dr. Michl

München, Bavaria, Germany

Schwerpunktpraxis und Tagesklinik für Hämatologie und Onkologie

Regensburg, Bavaria, Germany

Klinikum Rosenheim Medizinische Klinik II

Rosenheim, Bavaria, Germany

Universitätsklinikum Ulm Klinik für Innere Medizin I Gastroenterologie, Nephrologie

Ulm, Bavaria, Germany

Ambulantes Zentrum für Hämatologie & Onkologie

Cottbus, Brandenburg, Germany

BAG Onkologie am Filmpark

Potsdam, Brandenburg, Germany

ÜBAG Onkologische Kooperation Harz GbR

Goslar, Lower Saxony, Germany

Onkologische Schwerpunktpraxis

Hanover, Lower Saxony, Germany

Gemeinschaftspraxis Dr. Haytham Kamal und Dr. David C. Dorn

Hanover, Lower Saxony, Germany

Onkologie UnterEms Leer-Emden-Papenburg Dr. L. Müller

Leer, Lower Saxony, Germany

MVZ Onko Medical GmbH

Neustadt am Rübenberge, Lower Saxony, Germany

MVZ für Onkologie und Urologie GmbH

Wilhelmshaven, Lower Saxony, Germany

MVZ für Hämatologie und Onkologie Köln Am Sachsenring GmbH

Cologne, North Rhine-Westphalia, Germany

Evang. Kliniken Essen-Mitte (KEM) Internistische Onkologie

Essen, North Rhine-Westphalia, Germany

Praxis Internistischer Onkologie und Hämatologie (PIOH)

Frechen, North Rhine-Westphalia, Germany

Praxis für Hämatologie und internistische Onkologie

Ratingen, North Rhine-Westphalia, Germany

MVZ Kloster Paradiese GbR Schwerpunktpraxis für Hämatologie u Onkologie

Soest, North Rhine-Westphalia, Germany

Hämatologie - Onkologie - Stolberg

Stolberg, North Rhine-Westphalia, Germany

KHOP - Kalkan Hämatologie Onkologie Palliativmedizin

Wermelskirchen, North Rhine-Westphalia, Germany

SHG Klinikum Idar-Oberstein Med. Klinik I: Gastroenterologie, Nephrologie, Hämatologie, Onkologie

Idar-Oberstein, Rhineland-Palatinate, Germany

Onkologische Schwerpunktpraxis Speyer

Speyer, Rhineland-Palatinate, Germany

Gemeinschaftspraxis für Hämatologie und Onkologie GbR

Lebach, Saarland, Germany

Onkozentrum Dresden

Dresden, Saxony, Germany

BAG / Onkologische Gemeinschaftspraxis

Dresden, Saxony, Germany

Gemeinschaftspraxis Dr. Mohm / Dr. Siklaky / Mann

Dresden, Saxony, Germany

Praxis Dr. med. Jens Uhlig

Naunhof, Saxony, Germany

Praxis und Tagesklinik für Hämatologie/Onkologie

Zittau, Saxony, Germany

DRK Kliniken Berlin Köpenick Klinik für Allgemein-, Viszeral- & Minimalinvasive Chirurgie

Berlin, Germany

Evangelisches Waldkrankenhaus Spandau Innere Medizin I

Berlin, Germany

Hämatologisch-Onkologische Praxis Eppendorf (HOPE)

Hamburg, Germany

Überörtliche Gemeinschaftspraxis Schwerpunkt Haematologie, internist Onkologie & Palliativmedizin

Hamburg, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06787105

Related Trials

PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

NCT052868141 location

A Clinical Study of Arfolitixorin in Patients With mCRC

NCT069223833 locations

Randomized Controlled Trial of the Effects of Combined Resistance and AerobiC Exercise on Health-related Quality of Life in Patients Undergoing First-line Chemotherapy for Metastatic Colorectal Cancer (REACH)

NCT069389714 locations

Evaluation of a Diagnostic Test to Identify the Best Drugs for Treatment of Metastatic Colorectal Cancer

NCT071715541 location

The Phase-2 CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen Trial (CLOVER)

NCT066998367 locations